J. Cortes

Hematology · 2003–2022

A researcher in the Science corpus: 24 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Hematology — 175 citations into it
• Rheumatology — 102 citations into it

Whom J. Cortes trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. H. Kantarjian
2. M. Baccarani
3. Brian J. Druker
4. J. Apperley

Who trusts J. Cortes overall

1. M. Baccarani

Papers from J. Cortes's perspective

Ordered by how strongly the researchers J. Cortes trusts endorse each paper. Same corpus, a different order for every researcher.

1. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (Journal of Clinical Oncology)
2. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. (Cancer Cell)
3. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. (Blood)
4. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. (The Lancet Oncology)
5. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. (Journal of Clinical Oncology)
6. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
7. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (New England Journal of Medicine)
8. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (Blood)
9. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase… (Blood)
10. Updated clinical classification of pulmonary hypertension. (Journal of the American College of Cardiology)

Their papers

• Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. (2004) — 825 citations
• Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. (2007) — 718 citations
• International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. (2022) — 2,334 citations
• European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia (2020) — 1,281 citations
• Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. (2019) — 1,063 citations
• CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia (2018) — 812 citations
• Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial (2016) — 852 citations
• Selective BCL-2 Inhibition by ABT-199 Causes On Target Cell Death in Acute Myeloid Leukemia (2013) — 663 citations
• Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents (2013) — 667 citations
• A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias (2013) — 1,031 citations
• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013) — 1,917 citations
• Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias (2012) — 746 citations
• Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. (2011) — 799 citations
• Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. (2010) — 722 citations
• Molecular biology of bcr-abl1-positive chronic myeloid leukemia. (2009) — 722 citations
• Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (2009) — 1,280 citations
• Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. (2008) — 739 citations
• Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. (2006) — 1,311 citations
• Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. (2006) — 1,710 citations
• Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (2006) — 1,349 citations